|
|
|
|
LEADER |
01421nam a2200229 u 4500 |
001 |
EB002010903 |
003 |
EBX01000000000000001173802 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
220201 r ||| eng |
245 |
0 |
0 |
|a Ivabradine hydrochloride (Lancora)
|h Elektronische Ressource
|
246 |
3 |
1 |
|a CDR clinical review report for Lancora
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, June 2017
|
300 |
|
|
|a 1 PDF file (65 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH common drug review clinical review report
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK533838
|3 Volltext
|
082 |
0 |
|
|a 700
|
520 |
|
|
|a The objective of this review was to perform a systematic review of the beneficial and harmful effects of ivabradine 5 mg and 7.5 mg tablets for the treatment of stable chronic heart failure (HF) with left ventricular ejection fraction (LVEF) (d 35%) in adult patients with New York Heart Association (NYHA) class II or III HF who are in sinus rhythm with a resting heart rate e 77 bpm, to reduce the incidence of cardiovascular mortality and hospitalizations for worsening HF, administered in combination with standard chronic HF therapies
|